drug prices 2 years review the country based on the actual price, expensive and aging, and in addition has been pointed out that the drugs are being developed and the review, has led to the growth of health care costs.

drug sales are projected to reach 126 billion yen or more a year, therapeutic drug for lung cancer said to be especially patient cost per year approximately 35 million yen takes 'opzi-Bo' is used in patients with 30 times more than had originally been assumed.

expensive for medical expenses, not become heavy burden on patients to limit the country to bear part of the cost for the Ministry of finance, lead to financial pressure, about the price of "opzi-Bo", re consolidated policy measures without waiting for the revision of prices of drugs in April temporarily lower instructs the Ministry of health, labour and welfare. To suggest financial Council held next week, and lead to further increase of medical expenses in excess of 40000000000000 yen after Ministry of finance is 引ki下genakereba a price temporarily, a financial burden too heavy and even.